News Mixed results for experimental Alzheimer's therapies at CTAD The CTAD Alzheimer's meeting hears encouraging data for new drug candidates from the likes of Biogen, AriBio, and BMS - but also some disappointments.
News Leqembi sales grow again after subcutaneous approvals Biogen/Eisai's Alzheimer's drug Leqembi continued to grow in Q2, driven by a new subcutaneous version, but fell a little short of expectations.
News FDA clears at-home start dose for Alzheimer's drug Leqembi The FDA has cleared Eisai and Biogen's Leqembi Iqlik subcutaneous injection as a starting dose, removing the need for regular infusion clinic visits.
News Eisai claims UK grant to expand manufacturing site Eisai has been given a grant from the UK that will support a £48m plan to add cold chain capabilities to its facility in Hatfield, Hertfordshire.
News ASCO26: AZ triplet makes waves in frontline liver cancer EMERALD-3 suggests a triplet regimen based on AstraZeneca's Imfinzi and Imjudo could be practice-changing as a frontline hepatocellular carcinoma.
News Eisai, Biogen face delay to subcutaneous Leqembi Eisai and Biogen are facing a delay in the FDA review of injectable Leqembi for initial dosing in Alzheimer's, viewed as a key growth driver.
News Isomorphic adds MSD to partner roster, and other deals It's been a busy dealmaking week, with Isomorphic Labs, fresh from a $5 billion financing, adding MSD to its list of research alliances.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.